Evidence map›Paper›PMID 35195394›Full record

ArticleAnalytical chemistry2022

Enhancing Cysteine Chemoproteomic Coverage through Systematic Assessment of Click Chemistry Product Fragmentation.

Tianyang Yan, Andrew B Palmer, Daniel J Geiszler, Daniel A Polasky, Lisa M Boatner, Nikolas R Burton, Ernest Armenta, Alexey I Nesvizhskii, Keriann M Backus

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Multi-omic stratification of the missense variant cysteinome.bioRxiv : the preprint server for biology · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tianyang YanBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.
Andrew B PalmerBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.
Daniel J GeiszlerDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, United States.
Daniel A PolaskyDepartment of Pathology, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-0515-1735
Lisa M BoatnerBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.ORCID 0000-0003-0757-4982
Nikolas R BurtonBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.
Ernest ArmentaBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.
Alexey I NesvizhskiiDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, United States.
Keriann M BackusBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, United States.ORCID 0000-0001-8541-1404
University of California, Los Angeles · USUniversity of Michigan · US

Funding

COMPUTATIONAL TOOLS FOR MASS SPECTROMETRY-BASED INTERACTOME DATAR01GM094231 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 2010 to 2026
$5.4M
Proteogenomics of Cancer Training ProgramT32CA140044 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, ARVIND, SARTOR, MAUREEN AGNES · 2010 to 2024
$3.9M
NCI NIH HHS T32 CA140044NIGMS NIH HHS R01 GM094231
6 · The paper itself

Abstract

Mass spectrometry-based chemoproteomics has enabled functional analysis and small molecule screening at thousands of cysteine residues in parallel. Widely adopted chemoproteomic sample preparation workflows rely on the use of pan cysteine-reactive probes such as iodoacetamide alkyne combined with biotinylation via copper-catalyzed azide-alkyne cycloaddition (CuAAC) or "click chemistry" for cysteine capture. Despite considerable advances in both sample preparation and analytical platforms, current techniques only sample a small fraction of all cysteines encoded in the human proteome. Extending the recently introduced labile mode of the MSFragger search engine, here we report an in-depth analysis of cysteine biotinylation via click chemistry (CBCC) reagent gas-phase fragmentation during MS/MS analysis. We find that CBCC conjugates produce both known and novel diagnostic fragments and peptide remainder ions. Among these species, we identified a candidate signature ion for CBCC peptides, the cyclic oxonium-biotin fragment ion that is generated upon fragmentation of the N(triazole)-C(alkyl) bond. Guided by our empirical comparison of fragmentation patterns of six CBCC reagent combinations, we achieved enhanced coverage of cysteine-labeled peptides. Implementation of labile searches afforded unique PSMs and provides a roadmap for the utility of such searches in enhancing chemoproteomic peptide coverage.

Indexed as

Click ChemistryCysteineAlkynesAzidesCatalysisCopperCycloaddition ReactionHumansTandem Mass SpectrometryAlkynesAzidesCopperCysteine

Identifiers

PMID35195394
PMCPMC11832189
OpenAlexW4220994690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.